Trials / Terminated
TerminatedNCT03074825
Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma
Efficacy and Safety of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma: a Single-arm, Open-label, Multi-site, Exploratory Phase Ib Study
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Chipscreen Biosciences, Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B（Aurora B）、VEGFR/PDGFR/c-Kit、CSF-1R targets. This clinical trial is studying the efficacy and safety of chiauranib works in treating patients with relapsed or refractory non-Hodgkin's lymphoma, in the meantime, exploring the latent biomarkers accompany with chiauranib, as well as the relevancy of which and clinical benefit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chiauranib | Take 50mg orally once daily |
Timeline
- Start date
- 2017-05-09
- Primary completion
- 2017-08-15
- Completion
- 2019-02-14
- First posted
- 2017-03-09
- Last updated
- 2019-07-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03074825. Inclusion in this directory is not an endorsement.